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Consumers are increasingly concerned about
the quality and safety of many products pre-
sent in the diet of industrialized countries, in
particular, the use of artiﬁcial sweeteners, ﬂa-
vorings, colorings, preservatives, and dietary
supplements. General apprehension also
exists regarding the possible long-term health
effects of the raw materials and technologies
used for the packaging, sterilization, and dis-
tribution of foods. Of particular concern are
the potential carcinogenic effects of these
products and processes.
The experimental and epidemiologic data
currently available to evaluate the above car-
cinogenic risks are insufﬁcient and often unreli-
able because of the inadequate planning and
conduct of previous experiments. This inade-
quacy, combined with the general limited
knowledge about the safety and potential car-
cinogenic effects of substances widely present in
the industrialized diet, motivated the design of
an integrated project of mega-experiments in
1985 at the Cesare Maltoni Cancer Research
Center (CMCRC) of the European Ramazzini
Foundation (ERF). The products studied are
reported in Table 1. The products and agents
we selected for this project were those for
which committee debate and opinions had
often acted as surrogates for good laboratory
work. At present, over the course of the
project, 32 long-term bioassays have been
performed using > 25,000 rodents. Studies
have evaluated the carcinogenicity of 12 differ-
ent products, including the artiﬁcial sweetener
aspartame (APM).
In this article we present the results of the
mega-experiment on the carcinogenicity of
APM in which the sweetener was adminis-
tered in feed to Sprague-Dawley rats for the
life span.
APM, the methyl ester of the dipeptide
L-α-aspartyl-L-phenylalanine (C14H18N2O5),
is a widely used artificial sweetener with a
molecular weight of 294.3. Under particular
conditions (extreme pH, high temperature,
lengthy storage times), APM may be contami-
nated by the diketopiperazine (DKP) cyclo-
aspartylphenylalanine (Butchko et al. 2002a).
For more than 30 years, APM has been
widely used as a food additive because of its
very strong, sweet taste. The sweetening
power of APM is estimated to be 200 times
that of sucrose, whereas saccharin and cycla-
mate are 300 and 30 times sweeter, respec-
tively (Mazur 1984).
Initial commercial approval of APM in the
United States was granted by the Food and
Drug Administration (FDA 1974). The FDA
later approved the limited use of APM in solid
foods in 1981 and extended this authorization
to soft drinks in 1983. APM was eventually
approved as a general sweetener in 1996 (FDA
1981, 1983, 1996). In the European Union,
the safe use of APM was authorized in 1994
(EC Directive 1994). 
After saccharin, APM is the second most
used artificial sweetener in the world. It is
estimated that > 8,000 tons of APM are con-
sumed each year in the United States
(Hazardous Substances Data Bank 2005). In
terms of world consumption, APM represents
62% of the value of the intense sweetener
market (Fry 1999).
APM is found in > 6,000 products, includ-
ing carbonated and powdered soft drinks, hot
chocolate, chewing gum, candy, desserts,
yogurt, tabletop sweeteners, and some pharma-
ceutical products, such as vitamins and sugar-
free cough drops, and is estimated by the
Aspartame Information Center (2005) to be
consumed by > 200 million people worldwide.
Through dietary surveys performed in the
United States among APM consumers during
the period 1984–1992, the average APM daily
intake in the general population has been
shown to range from 2 to 3 mg/kg body
weight (bw). Consumption by children
2–5 years of age and by females of childbearing
age in these surveys ranged from about 2.5 to
5 mg/kg bw/day (Butchko et al. 2002b). APM
intake was also monitored in several other
regions, including seven European countries.
Although survey methodologies may have dif-
fered, the APM intake was remarkably consis-
tent across studies and was well below the
acceptable daily intake (ADI) both in the
United States (50 mg/kg bw) and in Europe
(40 mg/kg bw) (Butchko et al. 2002b).
Investigations into the metabolism of
APM have shown that, in rodents, nonhuman
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The Cesare Maltoni Cancer Research Center of the European Ramazzini Foundation has con-
ducted a long-term bioassay on aspartame (APM), a widely used artificial sweetener. APM was
administered with feed to 8-week-old Sprague-Dawley rats (100–150/sex/group), at concentra-
tions of 100,000, 50,000, 10,000, 2,000, 400, 80, or 0 ppm. The treatment lasted until natural
death, at which time all deceased animals underwent complete necropsy. Histopathologic evalua-
tion of all pathologic lesions and of all organs and tissues collected was routinely performed on
each animal of all experimental groups. The results of the study show for the ﬁrst time that APM,
in our experimental conditions, causes a) an increased incidence of malignant-tumor–bearing ani-
mals with a positive signiﬁcant trend in males (p ≤ 0.05) and in females (p ≤ 0.01), in particular
those females treated at 50,000 ppm (p ≤ 0.01); b) an increase in lymphomas and leukemias with
a positive significant trend in both males (p ≤ 0.05) and females (p ≤ 0.01), in particular in
females treated at doses of 100,000 (p ≤ 0.01), 50,000 (p ≤ 0.01), 10,000 (p ≤ 0.05), 2,000
(p ≤ 0.05), or 400 ppm (p ≤ 0.01); c) a statistically signiﬁcant increased incidence, with a positive
signiﬁcant trend (p ≤ 0.01), of transitional cell carcinomas of the renal pelvis and ureter and their
precursors (dysplasias) in females treated at 100,000 (p ≤ 0.01), 50,000 (p ≤ 0.01), 10,000
(p ≤ 0.01), 2,000 (p ≤ 0.05), or 400 ppm (p ≤ 0.05); and d) an increased incidence of malignant
schwannomas of peripheral nerves with a positive trend (p ≤ 0.05) in males. The results of this
mega-experiment indicate that APM is a multipotential carcinogenic agent, even at a daily dose of
20 mg/kg body weight, much less than the current acceptable daily intake. On the basis of these
results, a reevaluation of the present guidelines on the use and consumption of APM is urgent and
cannot be delayed. Key words: artiﬁcial sweetener, aspartame, carcinogenicity, lymphomas, malig-
nant schwannomas, rats, renal pelvis carcinomas. Environ Health Perspect 114:379–385 (2006).
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gastrointestinal tract into three constituents—
aspartic acid, phenylalanine, and methanol—
which are absorbed into the systemic
circulation (Ranney et al. 1976). For each
molecule of APM, one molecule of each con-
stituent is produced. After absorption, they are
then used, metabolized, and/or excreted by the
body following the same metabolic pathways
as when consumed through the ordinary diet:
aspartate is transformed into alanine plus
oxaloacetate (Stegink 1984); phenylalanine is
transformed mainly into tyrosine and, to a
smaller extent, phenylethylamine and phenyl-
pyruvate (Harper 1984); and methanol is
transformed into formaldehyde and then to
formic acid (Opperman 1984).
APM was not genotoxic in the following
tests: dominant lethal mutation assay in rats,
host-mediated assay in rats and mice, in vivo
cytogenetic assay in rats, and the Ames test
(Kotsonis and Hjelle 1996). Results of an assay
to measure induction of unscheduled DNA
synthesis in rat hepatocytes treated with APM
in vitro were negative, indicating the absence of
APM-induced DNA damage (Jeffrey and
Williams 2000). In a test for the induction of
chromosomal aberration in bone marrow cells
of male Swiss mice, Mukhopadhyay et al.
(2000) reported that a mixture of APM (up to
350 mg/kg) and a second sweetener, acesul-
fame potassium (up to 150 mg/kg) adminis-
tered by gavage was negative. However, a
dose-related increase in the percentage of cells
with chromosomal aberrations was noted with
increasing doses of the two sweeteners, even
though the increase was not statistically signiﬁ-
cant (Mukhopadhyay et al. 2000).
Two long-term feeding carcinogenicity
bioassays on APM were performed on rats and
one on mice in the early 1970s by the pro-
ducer Searle & Co. Results were reviewed by
the FDA and then summarized in the Federal
Register (FDA 1981). To date, the details of
the experiments have not been published.
In the ﬁrst study, groups of 40 male and
40 female Sprague-Dawley rats were treated
with 1, 2, 4, or 6–8 g/kg bw/day of APM in
the diet. The treatment started at 4 weeks of
age and lasted for a period of 104 weeks. A
control group of 60 rats per sex was fed the
same diet without APM. At the end of the
treatment, all surviving animals were sacriﬁced
and their brains, as well as other organs (not
speciﬁed in the report), were examined histo-
logically. Brain tumors were observed in 7 of
155 (4.5%) exposed males versus 1 of 59
(1.7%) controls, and in 5 of 158 (3.2%)
exposed females versus 0 of 59 (0%) controls.
Overall, the FDA considered the study to be
negative with regard to the carcinogenicity of
APM (FDA 1981). 
In the second study, groups of 40 male
and 40 female Sprague-Dawley rats were
exposed to APM, at doses of 2 and 4 g/kg
bw/day, through their mothers’ diet both
in utero and during lactation, and then for
104 weeks with APM in their own diets. A
control group of 60 rats per sex was fed the
same diet without APM. The animals were
necropsied at the time of death or at
104 weeks after weaning. Three brain tumors
were observed among control males and one
among control females. Brain tumors were
also observed in two males and one female in
the 2 g/kg bw group, and in one male and
one female in the 4 g/kg bw group. Again,
the FDA considered the study to be negative
with regard to the carcinogenicity of APM
(FDA 1981). 
Regarding the third chronic APM study, in
this case performed on mice, the FDA reported
that the results did not show any treatment-
related carcinogenic effect. In this experiment,
as reported by Molinary (1984), groups of 36
male and 36 female mice were fed 1, 2, or
4 g/kg bw/day until 110 weeks of age. A group
of 72 males and 72 females served as the con-
trol. There were no treatment-related effects on
survival and behavior, nor were any lesions
recorded during macroscopic or microscopic
analysis.
An APM carcinogenicity study was also
conducted in Japan during this period (Ishii
1981; Ishii et al. 1981). Groups of 86 male
and 86 female Wistar rats were treated with
APM in feed at doses of 0, 1, 2, or 4 g/kg
bw/day from 6 to 110 weeks of age. No
increase in the incidence of brain tumors was
observed in the treated groups compared with
the controls. Exhaustive experimental details
of this study were not published.
Epidemiologic studies to evaluate the rela-
tionship between APM intake and cancer
development in humans are not currently
available.
Although all of the aforementioned stud-
ies were considered negative with respect to
the carcinogenicity of APM, in our opinion,
these studies did not comply with today’s
basic requirements for testing the carcino-
genic potential of a physical or chemical
agent, in particular concerning the number of
animals for each experimental group and the
duration of the experiment until 110 weeks of
age of the animals.
For these reasons, and in light of the ever-
increasing diffusion of APM in the diet of
industrialized countries (particularly in prod-
ucts consumed by young children and preg-
nant women), we considered it important to
perform a mega-experiment following today’s
internationally recognized good laboratory
practices for carcinogenicity bioassays and,
more speciﬁcally, the life-span carcinogenicity
bioassay design followed for many years at the
CMCRC and described in previous publica-
tions (Soffritti et al. 1999, 2002c).
Materials and Methods
APM, as a food-grade material, was produced
by Nutrasweet and supplied by Giusto
Faravelli S.p.A. (Milan, Italy). Its purity was
> 98%: DKP was < 1.5% and L-phenylalanine
was < 0.5%. An infrared absorption spec-
trophotometer assay was used to determine
APM purity. An assumed daily intake by
humans of 5,000, 2,500, 500, 100, 20, 4, or
0 mg/kg bw was simulated by adding APM to
the standard Corticella diet (Laboratori
Dottori Piccioni, Milan Italy), used for
30 years at the CMCRC/ERF laboratory, at
concentrations of 100,000, 50,000, 10,000,
2,000, 400, 80, or 0 ppm. The APM daily
assumption in milligrams per kilogram body
weight was calculated considering the average
weight of a rat for the duration of the experi-
ment as 400 g, and the average consumption
of feed as 20 g/day, both for males and females.
APM was administered with feed ad libitum to
Sprague-Dawley rats (100–150/sex/group).
The experiment started when the animals were
8 weeks of age, and the treatment lasted until
natural death. Control animals received the
Soffritti et al.
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Table 1. Beverages and diet products studied at the CMCRC/ERF: status of studies.
No. of Animals
No. Products bioassays Species No. Study status 
1 Water in polyvinyl chloride bottles 2 Rata  2,200 Pb 
2 Coca-Cola 4 Rata  1,999 RP
3 Pepsi Cola 1 Rat 400 E
4 Ethyl alcohol (10% vol/vol) 4 Rat,a mouse 1,458 Pc 
5 Sucrose 1 Rat 400 E
6 APM 6 Rat, mousea  4,460 BO, PPd 
7 Sucralose 1 Mousea  760 BO
8 Caffeine 1 Rat 800 E
9 Vitamin A 5 Rat 5,100 PPe 
10 Vitamin C 5 Rat 3,680 E
11 Vitamin E 5 Rat 3,680 E
12 Feed sterilized by gamma radiation 1 Rata  2,000 E
Total 36 26,937
Abbreviations: BO, biophase ongoing; E, in elaboration; P, published; PP, partially published; RP, ready for publication.
aTreatment started from embryonic life. bData from Maltoni et al. (1997). cData from Soffritti et al. (2002a). dData from
Soffritti et al. (2005). eData from Soffritti et al. (1992). same feed without APM. The experiment was
conducted according to Italian law regulating
the use of animals for scientific purposes
(Decreto Legislativo 116 1992), which pro-
vides the guidelines on how to treat animals
humanely and without suffering.
Rodents used for the experiment were male
and female Sprague-Dawley rats from the
colony of the CMCRC/ERF. This colony of
rats has been employed for various experiments
in the laboratory for nearly 30 years, and
extensive historical data are available on the
tumor incidence among untreated rats. All
control animals were monitored for feed and
water consumption and body weight for their
life span and, upon death, underwent complete
necropsy and histopathologic evaluation.
The health status of the animals was regu-
larly checked by the veterinarians of the local
and national health services. Before matching,
the breeders were clinically observed for their
health status, in order to exclude any diseased
animals, and the experimental animals were
clinically examined monthly until the end of
the experiment.
At 4–5 weeks of age, after weaning, the
experimental animals were randomized in
order to have no more than one male and one
female from each litter in the same group.
They were then housed, in groups of ﬁve, in
Makrolon cages (41 cm × 25 cm × 15 cm),
with stainless-steel wire tops and a shallow
layer of white wood shavings as bedding, and
kept in rooms used only for this experiment,
at a temperature of 23 ± 2°C and relative
humidity of 50–60%. 
Once a week for the ﬁrst 13 weeks, then
every 2 weeks until the rats were 110 weeks of
age, the mean daily drinking water and feed
consumption was measured per cage, and
body weight was measured individually.
Measurement of body weight continued every
8 weeks until the end of the experiment. The
animals were clinically examined for gross
changes every 2 weeks for the duration of the
experiment. To evaluate the status and behav-
ior of the animals and to limit the post-
mortem modifications (pmm), a patrol was
performed three times daily from Monday
through Friday and twice on Saturdays and
Sundays and holidays. Dead animals were
registered and kept refrigerated at 4°C until
necropsy. Based on this procedure [part of
our longstanding standard operating proce-
dures (SOP)], very few animals were affected
by pmm, and only on very rare occasions did
this interfere with the ability to histologically
diagnose and interpret some lesions.
The biophase ended at 151 weeks, with the
death of the last animal at the age of 159 weeks.
Upon death, the animals underwent complete
necropsy. Histopathology was routinely per-
formed on the following organs and tissues of
each animal from each group: skin and subcu-
taneous tissue, mammary gland, the brain
(three sagittal sections), pituitary gland, Zymbal
glands, salivary glands, Harderian glands, cra-
nium (ﬁve sections, with oral and nasal cavities
and external and internal ear ducts), tongue,
thyroid, parathyroid, pharynx, larynx, thymus
and mediastinal lymph nodes, trachea, lung and
mainstem bronchi, heart, diaphragm, liver,
spleen, pancreas, kidneys, adrenal glands,
esophagus, stomach (fore and glandular), intes-
tine (four levels), urinary bladder, prostate,
gonads, interscapular brown fat pad, subcuta-
neous and mesenteric lymph nodes, and other
organs or tissues with pathologic lesions. All
organs and tissues were preserved in 70% ethyl
alcohol, except for bones, which were ﬁxed in
10% formalin and then decalciﬁed with 10%
formaldehyde and 20% formic acid in water
solution. The normal specimens were trimmed
following the CMCRC/ERF laboratory SOP.
Trimmed specimens were processed as parafﬁn
blocks, and 3–5 µm sections of every specimen
were obtained.
Sections were routinely stained with hema-
toxylin and eosin (H&E). Immunohisto-
chemical staining for S100 was performed to
characterize malignant schwannoma, whereas
chromogranin A staining was used to charac-
terize olfactory neuroblastomas. For S100
staining, we used a polyclonal rabbit anti-S100
(Z0311; Dakocytomation, Carpinteria, CA,
USA) as primary antibody, whereas for chro-
mogranin A staining, we used a polyclonal rab-
bit anti-human chromogranin A (N1535,
Dakocytomation) (Information Center for
Immunohistochemistry 2005).
Two statistical tests were used to analyze
neoplastic and nonneoplastic lesion incidence
Aspartame carcinogenicity
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Figure 1. Comparison of untreated and treated male and female rats. (A) Mean daily feed consumption in males. (B) Mean daily feed consumption in females.
(C) Mean body weights in males (M) and females (F). (D) Survival in males. (E) Survival in females. The arrow indicates the start of the experiment at 8 weeks of age. data. We used the Cochran-Armitage trend
test (Armitage 1971; Gart et al. 1979) to test
for linear trends in tumor incidence. We also
used the poly-k test (Bailer and Portier 1988;
Piegorsch and Bailer 1997; Portier and Bailer
1989), a survival-adjusted quantal response
modiﬁcation of the Cochran-Armitage test that
takes survival into account. The tests used and
the resulting p-values are reported in the tables.
Results
The study proceeded smoothly without unex-
pected occurrences. We observed no differ-
ences in water consumption between the
treated and the untreated groups, whereas a
dose-related difference in feed consumption
was observed between the various treated
groups and the control group in both males
and females (Figure 1A,B). No substantial
differences in mean body weight were
observed between the treated and control
groups, apart from a slight decrease in females
treated at 100,000 ppm APM (Figure 1C).
No substantial difference in survival was
observed among the groups (Figure 1D,E).
No evident behavioral changes were
observed among treated animals compared
with controls. In animals exposed to the high-
est dose of APM, yellowing of the coat was
observed; this change had previously been
observed in our laboratory in rats exposed to
formaldehyde administered with drinking
water (Soffritti et al. 2002b).
The carcinogenic effects of APM are
reported in Table 2 for males and Table 3 for
females. Multiple tumors of different types
and sites; of different types in the same site; of
the same types in bilateral organ; of the same
types in the skin, subcutaneous tissue, or
mammary glands; or at distant sites of diffuse
tissue (i.e., bones and skeletal muscle) were
plotted as single/independent tumors.
Multiple tumors of the same type in the same
tissue and organ, apart those above men-
tioned, were plotted only once.
Total malignant tumors. The incidence of
animals bearing malignant tumors occurred
with a significant positive trend in males
(p ≤ 0.05) and in females (p ≤ 0.01), as
reported in Tables 2 and 3. A statistically sig-
niﬁcant increase of the incidence of malignant
tumors was observed in females treated at
50,000 ppm (p ≤ 0.01) compared with the
control group (Table 3). Tumor types that
contributed most are presented below.
Lymphomas/leukemias. The data on the
occurrence of lymphomas/leukemias, reported
in Tables 2 and 3, indicate that APM causes a
signiﬁcant positive trend in males (p ≤ 0.05)
and in females (p ≤ 0.01). Compared with
untreated control groups, the increased inci-
dence of lymphomas/leukemias in treated
females was statistically signiﬁcant at doses of
100,000 (p ≤ 0.01), 50,000 (p ≤ 0.01), 10,000
(p ≤ 0.05), 2,000 (p ≤ 0.05), or 400 ppm
(p ≤ 0.01). The most frequent histocytotypes
observed in the experiment were lympho-
immunoblastic lymphomas, mainly involving
lung and mediastinal/peripheral nodes, and
histiocytic sarcomas, involving mainly lung,
liver, spleen, and nodes. The distribution of
lymphomas/leukemias by histocytotypes is pre-
sented in Table 4. The differential diagnoses
were based on the morphologic criteria fol-
lowed in our laboratory for several decades and
are in line with the guidelines of the
International Classiﬁcation of Rodent Tumors
[International Agency for Research on Cancer
(IARC) 1993]. Lymphomas/leukemias (this
term includes all types of hemolympho-
sarcomas and leukemias) are neoplasias arising
from hemolymphoreticular tissues, and their
aggregation is widely used in experimental car-
cinogenesis because both solid and circulating
phases are present in many lymphoid neo-
plasms, and distinction between them is artiﬁ-
cial (Harris et al. 2001).
Preneoplastic and neoplastic lesions of the
renal pelvis and ureter. The incidences of pre-
neoplastic and neoplastic lesions of the transi-
tional cell epithelium of the renal pelvis and
ureter are reported in Tables 2 and 3. A dose-
related increase in the incidence of dysplastic
hyperplasias and dysplastic papillomas of the
renal pelvis and ureter was observed in females.
Carcinomas in females occurred with a positive
trend (p ≤ 0.05), and the incidence in females
exposed at 100,000 ppm was significantly
higher (p ≤ 0.05) compared with the controls.
Soffritti et al.
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Table 2. Incidence of the preneoplastic and neoplastic lesions in male Sprague-Dawley rats in a life-span feed carcinogenicity study of APM.
Total animals Animals bearing dysplastic lesions and
Malignant tumorsa bearing carcinomas of the renal pelvis and uretera Animals bearing peripheral nerve
Tumor-bearing Total tumors lymphomas/ Dysplastic Dysplastic malignant schwannomasa
Dose, ppm Animals animals
b Per 100 leukemiasa,b hyperplasias papillomas Carcinomas Total Cranial Other sites Totalb
(mg/kg bw) at start No. % No. animals No. % No. % No. % No. % No. % No. % No. % No. %
100,000 (5,000) 100 43 43.0 55 55.0 29 29.0 3 3.0 0 — 1 1.0 4 4.0 3 3.0 1 1.0 4 4.0
50,000 (2,500) 100 38 38.0 45 45.0 20 20.0 2 2.0 0 — 1 1.0 3 3.0 3 3.0 0 — 3 3.0
10,000 (500) 100 34 34.0 42 42.0 15 15.0 2 2.0 0 — 1 1.0 3 3.0 2 2.0 0 — 2 2.0
2,000 (100) 150 60 40.0 69 46.0 33 22.0 4 2.7 0 — 1 0.7 5 3.3 2 1.3 0 — 2 1.3
400 (20) 150 48 32.0 52 34.7 25 16.7 4c 2.7 1c 0.7 0c —5 c 3.4 1 0.7 2 1.3 3 2.0
80 (4) 150 44 29.3 49 32.7 23 15.3 3c 2.0 0c —0 c —3 c 2.0 1 0.7 0 — 1 0.7
0 (0) 150 53 35.3* 59 39.3 31 20.7*,# 1 0.7 0 — 0 — 1 0.7 1 0.7 0 — 1 0.7*,#
aThe tumor rates are based on the number of animals examined (necropsied). bp-Values associated with the trend test are near the control incidence. cTissues from 149 animals were
analyzed. *Statistically signiﬁcant (p ≤ 0.05) using Cochran-Armitage test. #Statistically signiﬁcant (p ≤ 0.05) using poly-k test (k = 3). 
Table 3. Incidence of the preneoplastic and neoplastic lesions in female Sprague-Dawley rats in a life-span feed carcinogenicity study of APM.
Total animals Animals bearing dysplastic lesions and
Malignant tumorsa bearing carcinomas of the renal pelvis and uretera,b,c Animals bearing peripheral nerve
Tumor-bearing Total tumors lymphomas/ Dysplastic Dysplastic malignant schwannomasa
Dose, ppm Animals animals
b,c Per 100 leukemiasa,b,c hyperplasias papillomas Carcinomas
d Total Cranial Other sites Totalb
(mg/kg bw) at start No. % No. animals No. % No. % No. % No. % No. % No. % No. % No. %
100,000 (5,000) 100 51 51.0 64 64.0 25 25.0## 8 8.0 3 3.0 4 4.0# 15 15.0## 1 1.0 1 1.0 2 2.0
50,000 (2,500) 100 58 58.0## 84 84.0 25 25.0## 6e 6.1 1e 1.0 3e 3.0 10e 10.1## 1 1.0 0 — 1 1.0
10,000 (500) 100 40 40.0 62 62.0 19 19.0# 6 6.0 1 1.0 3(4) 3.0 10 10.0## 1 1.0 0 — 1 1.0
2,000 (100) 150 67 44.7 86 57.3 28 18.7# 6 4.0 1 0.7 3(4) 2.0 10 6.7# 1 0.7 2 1.3 3 2.0
400 (20) 150 70 46.7 95 63.3 30 20.0## 5 3.3 1 0.7 3 2.0 9 6.0# 0—0—0 —
80 (4) 150 64 42.7 85 56.7 22 14.7 4 2.7 1 0.7 1 0.7 6 4.0 1 0.7 1 0.7 2 1.3
0 (0) 150 55 36.7** 69 46.0 13 8.7**,# 2 1.3** 0 —* 0 — 2 1.3**,## 0—0—0 —
aThe tumor rates are based on the number of animals examined (necropsied). bp-Values corresponding to pairwise comparisons between the controls and the dosed group are near the
dosed group incidence . cp-Values associated with the trend test are near the control incidence. dValues in parentheses indicate the number of tumors (one animal can bear bilateral
tumors). eTissues from 99 animals were analyzed. *Statistically significant (p ≤ 0.05) using Cochran-Armitage test. **Statistically significant (p ≤ 0.01) using Cochran-Armitage test.
#Statistically signiﬁcant (p ≤ 0.05) using poly-k test (k = 3). ##Statistically signiﬁcant (p ≤ 0.01) using poly-k test (k = 3).Carcinomas were also observed among males
treated at 100,000, 50,000, 10,000, or
2,000 ppm. In females, dysplastic lesions and
carcinomas combined show a signiﬁcant posi-
tive trend (p ≤ 0.01) and a statistically signiﬁ-
cant increase in those treated at 100,000
(p ≤ 0.01), 50,000 (p ≤ 0.01), 10,000
(p ≤ 0.01), 2,000 (p ≤ 0.05), or 400 ppm
(p ≤ 0.05). A 3-fold increase is also observed in
the group treated with 80 ppm. We did not
observe substantial differences in the incidence
of inflammation between males and females
treated at the different doses, compared with
controls. Increased incidence of calcification
was observed in females, particularly in those
treated at 100,000 ppm (39%), 50,000 ppm
(25%), or 10,000 ppm (19%), compared with
controls (8%); this effect was not observed in
males. Although transitional cell carcinomas of
the renal pelvis and ureter are extremely rare in
male and female untreated rats, the APM male
and female groups had a total of 21 transitional
cell carcinomas of the renal pelvis, whereas the
controls had none. Microscopically, the carci-
nomas were invading, with various levels of
extension, the papilla and the kidney
parenchyma; the cells were of transitional type,
and several mitotic figures were present
(Figure 2A,B).
Malignant schwannomas of peripheral
nerves. As shown in Table 2, the incidence of
malignant schwannomas of the peripheral
nerves occurred with a positive trend (p ≤ 0.05)
in males. In females, nine malignancies were
observed among treated animals of the different
dosage groups, and none among the controls
(Table 3). All lesions, in males and females,
diagnosed as malignant schwannomas were
positive for S100 staining. The most frequent
site of origin of the malignant schwannomas
was in the cranial nerves (72%); the other cases
arose at the spinal nerve roots. Microscopically,
malignant schwannomas invaded the soft tis-
sues locally. Metastases of cranial nerve malig-
nant schwannomas were observed in three
males treated at the highest dose. The metas-
tases were found in submandibular lymph
nodes in two cases, and the tumor metastatized
to the lung and liver in one case. Histologically
the feature of malignant schwannomas was
Antoni B type (Figure 2C,D).
Preneoplastic and neoplastic lesions of the
olfactory epithelium. Incidence of hyperplasia
of the olfactory epithelium increased with a
signiﬁcant positive trend in males and females.
The observed incidences were, respectively,
14.0% and 18.0% in males and females
exposed at 100,000 ppm, 12.0% and 21.0%
at 50,000 ppm, 7.0% and 17.0% at
10,000 ppm, 2.7% and 8.7% at 2,000 ppm,
6.0% and 7.3% at 400 ppm, 2.0% and 3.3%
at 80 ppm, and 0.7% and 4.0% at 0 ppm.
The differences were statistically significant
(p ≤ 0.01) at 100,000, 50,000, or 10,000 ppm
in both males and females and at 400 ppm in
males. Among females treated at the highest
dose, one case of dysplastic hyperplasia, one
adenoma, and one olfactory neuroblastoma
were observed. The neuroblastoma invaded
the cranium, compressing the forebrain, and
was positive for chromogranin A immuno-
histochemical staining.
Malignant brain tumors. Concerning the
incidence of malignant tumors in the brain, it
should be noted that, as previously reported
(Soffritti et al. 2005), 12 malignant tumors
(10 gliomas, 1 medulloblastoma and 1 menin-
gioma) were observed, without dose relation-
ship, in male and female APM-treated groups,
whereas none were observed in controls.
Other malignant tumors. The other
malignant tumors were among those com-
monly observed in Sprague-Dawley rats, apart
Aspartame carcinogenicity
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Table 4. Incidence and distribution by hystocytotype of lymphomas/leukemias in female Sprague-Dawley rats in a life-span feed carcinogenicity study of APM.
Lymphomas/leukemiasa
Total lymphomas/ Lymphoblastic Lymphoblastic Lymphocytic Lymphoimmunoblastic Histiocytic Monocytic Myeloid
Dose, ppm Animals leukemiasb lymphoma leukemia lymphoma lymphoma sarcoma leukemia leukemia
(mg/kg bw) at start No. % No. % No. % No. % No. % No. % No. % No. %
100,000 (5,000) 100 25 25.0## 1 4.0 0 — 2 8.0 11 44.0 7 28.0 2 8.0 2 8.0
50,000 (2,500) 100 25 25.0## 2 8.0 0 — 0 — 10 40.0 8 32.0 4 16.0 1 4.0
10,000 (500) 100 19 19.0# 2 10.5 0 — 2 10.5 3 15.8 10 52.6 2 10.5 0 —
2,000 (100) 150 28 18.7# 5 17.8 1 3.6 1 3.6 8 28.6 8 28.6 4 14.3 1 3.6
400 (20) 150 30c 20.0## 7 23.3 0 — 2 6.7 8 26.7 9 30.0 5 16.7 0 —
80 (4) 150 22 14.7 3 13.6 0 — 5 22.7 6 27.2 6 27.3 2 9.1 0 —
0 (0) 150 13 8.7**,# 2 15.4 0 — 2 15.4 5 38.5 4 30.8 0 — 0 —
aPercentage of animals bearing speciﬁc histocytotype refer to the total number of animals bearing lymphomas/leukemias. bPercentage of animals at start to bear lymphomas/leukemias.
cOne animal had two types of neoplasias: lymphoblastic lymphoma and histiocytic sarcoma. **Statistically signiﬁcant (p ≤ 0.01) using Cochran-Armitage test. #Statistically signiﬁcant
(p ≤ 0.05) using poly-k test (k = 3). ##Statistically signiﬁcant (p ≤ 0.01) using poly-k test (k = 3). 
Figure 2. (A) Carcinoma of the renal pelvis in a female rat administered 100,000 ppm APM in feed; H&E;
magniﬁcation, 25×; bar = 500 µm. (B) Detail of the carcinoma shown in (A); H&E; magniﬁcation, 400×; bar =
20 µm. (C) Malignant schwannoma of cranial nerves resembling Antoni B type pattern in a male rat admin-
istered 100,000 ppm APM in feed; H&E; magnification, 200×; bar = 50 µm. (D) Immunohistochemical
characterization with S100 protein of the schwannoma shown in (C); magniﬁcation, 1,000×; bar = 10 µm.
A B
C DSoffritti et al.
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from two transitional cell carcinomas of the
bladder observed in males exposed to
10,000 ppm, one in females exposed to
2,000 ppm, and none among the controls.
Because this type of tumor is extremely rare
among the historical controls of our colony of
Sprague-Dawley rats, this occurrence cannot
be disregarded.
Historical controls. Over the last 20 years
in our laboratory, when we consider only
groups of > 100 animals/sex, the numbers of
the untreated males and females total 1,934
and 1,945 respectively. Concerning the renal
pelvis and ureter transitional cell carcinomas,
no carcinomas were observed in either males
or females. The overall incidence of malignant
schwannomas was 0.5% (range, 0–2.0%) in
males and 0.1% (range, 0–1.0%) in females.
The overall incidence of lymphomas/
leukemias was 20.7% (range, 8.0–30.9%) in
males and 12.4% (range, 7.0–18.4%) in
females. The overall incidence of olfactory
neuroblastoma was 0.1% (0–1.8%) in both
males and females.
When we also consider control groups of
< 100 animals/sex, the numbers of untreated
males and females total 2,265 and 2,274,
respectively. The overall incidence of the renal
pelvis and ureter transitional cell carcinomas
was 0.04% (range, 0–1.0%) in females, whereas
no carcinomas were observed in males. The
overall incidence of malignant schwannomas
was 0.4% (range, 0–2.0%) in males and 0.1%
(range, 0–2.0%) in females. The overall inci-
dence of lymphomas/leukemias was 20.6%
(range, 8.0–30.9%) in males and 13.3% (range,
4.0–25.0%) in females. The overall incidence
of olfactory neuroblastomas was 0.1% (range,
0–1.8%) in both males and females.
Discussion
The mega-experiment performed in our labo-
ratory on APM (administered with feed to
Sprague-Dawley rats from 8 weeks of age until
natural death) has shown for the ﬁrst time the
multipotential carcinogenic effects of this
compound. In fact, the results indicate that
APM causes, in our experimental conditions,
a) an increased incidence of malignant-
tumor–bearing animals with a positive signiﬁ-
cant trend in males (p ≤ 0.05) and in females
(p ≤ 0.01), particularly in the females treated
at 50,000 ppm (p ≤ 0.01); b) a statistically sig-
niﬁcant dose-related increase of the incidence
of lymphomas/leukemias in females treated at
the doses of 100,000 (p ≤ 0.01), 50,000
(p ≤ 0.01), 10,000 (p ≤ 0.05), 2,000
(p ≤ 0.05), or 400 ppm (p ≤ 0.01) and a posi-
tive signiﬁcant trend in both males (p ≤ 0.05)
and females (p ≤ 0.01); c) in females, dysplastic
lesions and carcinomas of the renal pelvis and
ureter combined show a significant positive
trend (p ≤ 0.01) and a statistically signiﬁcant
increase in those treated at 100,000 (p ≤ 0.01),
50,000 (p ≤ 0.01), 10,000 (p ≤ 0.01), 2,000
(p ≤ 0.05), or 400 ppm (p ≤ 0.05); and d)a n
increased incidence of malignant schwannomas
of the peripheral nerves with a positive trend
(p ≤ 0.05) in males.
The increase in lymphomas/leukemias in
APM-treated females could be related to its
metabolite methanol, which is in turn metabo-
lized to formaldehyde in both humans and rats
(Ranney et al. 1976). In fact, previous experi-
ments performed at the CMCRC laboratory
have shown that a) methanol administered in
drinking water, at doses ranging from 20,000
to 500 ppm, induced a statistically signiﬁcant
increase in the incidence of lymphomas/
leukemias in female rats (Soffritti et al. 2002a);
b) a dose-related increase in the incidence of
lymphomas/leukemias was also observed in
females treated with formaldehyde, adminis-
tered in drinking water at doses ranging from
1,500 to 50 ppm (Soffritti et al. 1989, 2002b);
and c) the same effect was observed in females
treated with the gasoline oxygenated additive
methyl-tert-butyl ether (MTBE), which metab-
olizes to methanol (Belpoggi et al. 1995).
The important role of formaldehyde in the
induction of hematologic malignancies in
rodents is further highlighted by these results.
In a recent reevaluation of the carcinogenicity
of formaldehyde by the IARC (in press), strong
(although not considered sufﬁcient) evidence
of an association between formaldehyde expo-
sure and leukemias in humans was found. 
Moreover, carcinogenic effects for the renal
pelvis and ureter, peripheral nerves and prolif-
erative changes of the olfactory epithelium
were not observed in the long-term bioassays
performed in the same conditions at the
CMCRC on methanol, MTBE, or formalde-
hyde. To investigate if the other two metabo-
lites of APM are responsible for inducing these
lesions, it is of paramount importance to per-
form adequate life-span carcinogenicity studies
on aspartic acid or phenylalanine.
In a long-term carcinogenicity study on
monosodium aspartate (MSA) administered
with drinking water to groups of 50 male and
50 female Fischer-344 rats (beginning at
6 weeks of age for 100 weeks and then sacri-
ﬁced), a dose-related hyperplasia of the renal
pelvis was observed in males and in females
(Kitahori et al. 1996). The same effect was
found by the same group of investigators in
another study in which MSA was administered
in drinking water to groups of male and female
Fischer-344 rats to evaluate its promoting
activity of carcinogenesis of the transitional
epithelium of the renal pelvis (Kitamura et al.
1996). In both studies, clear evidence was pro-
vided of a relationship between MSA treat-
ment and transitional cell hyperplasia. The
authors indicated that calciﬁcation could have
an important role in inducing simple and pap-
illary hyperplasia of the renal pelvis transitional
cell epithelium and, consequently, in the
induction of transitional cell tumors. In our
study performed on 1,800 Sprague-Dawley
rats, which are less susceptible to the sponta-
neous development of nephropathies than
Fischer rats, we observed a dose-related, statis-
tically signiﬁcant increase in the incidence of
dysplastic hyperplasia and carcinoma of the
renal pelvis in females, but none in males,
compared with the controls. The fact that we
observed an increased incidence of kidney cal-
cification in females and not in males, com-
pared with the controls, gives added weight to
the hypothesis that aspartic acid may cause pre-
neoplastic and neoplastic lesions of the renal
pelvis, and that calciﬁcation may be the mecha-
nism responsible for this effect.
The carcinogenic effects of APM observed
in our experiment are in contrast with the
results obtained with long-term carcinogenic-
ity bioassays, performed almost 30 years ago
on Sprague-Dawley rats, which did not reveal
APM to have any carcinogenic effects (FDA
1981). There are several reasons that can
explain this difference. First of all, in our
experiment the number of animals per sex per
group was much greater, allowing a more
thorough and reliable statistical analysis.
Second, in our experiment, rodents were not
killed at 110 weeks of age but rather were
observed until natural death, to allow APM to
fully express its carcinogenic potential. Had
we stopped the experiments at 110 weeks of
age, we would most likely never have demon-
strated the carcinogenicity of important
industrial compounds such as xylenes, man-
cozeb, vinyl acetate monomer (Soffritti et al.
2002c), and toluene (Soffritti et al. 2004).
Finally, concerning the absence of carcino-
genic effects observed in the experiment per-
formed on Wistar rats (Ishii 1981; Ishii et al.
1981), it cannot be disregarded that this strain
is more resistant than Sprague-Dawley rats to
developing cancer, a characteristic shown in our
experiments on benzene (Maltoni et al. 1989).
Moreover, the aforementioned experiment on
Wistar rats was terminated at the age of
110 weeks. Given these differences, the results
of the Wistar rat study are not comparable with
those performed on Sprague-Dawley rats.
Conclusions
Our study shows that APM is a multi-
potential carcinogenic compound whose car-
cinogenic effects are evident even at a daily
dose of 20 mg/kg bw, much less than the cur-
rent ADI for humans in Europe (40 mg/kg
bw) and in the United States (50 mg/kg bw).
The results of carcinogenicity bioassays in
rodents are consistent predictors of human
cancer risks (Huff 1999; Rall 1995; Tomatis
et al. 1989). The results of our study therefore
call for an urgent reexamination of the pre-
sent guidelines on the use and consumptionAspartame carcinogenicity
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of APM. The decision to use experimental
data to protect public health is important
because the time span of widespread APM use
is still too brief to have produced solid epi-
demiologic data. Moreover, it is unlikely that
sufﬁcient epidemiologic data will be available
in the near future, given the difﬁculty of ﬁnd-
ing a control group that has not been exposed
to this widely diffused compound.
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